Triveni
58 employees on LinkedIn · 10 known investors
Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases. The biotech company focuses on targeting the underlying biology of disease to change the standard of care for patients.
Founders & leadership
VP
Vishal PatelinChief Executive Officer
Investors · 10
Atlas VentureCambridge · $500K – $1M
Borealis VenturesHanover · $1M – $2.5M
Borealis VenturesHanover
Magnetic VenturesBoston · $1M – $6M
OrbiMedNew York · $1M – $75M
Ascenta CapitalreportedWilmington
Fidelity InvestmentsreportedBoston
InvusreportedNew York
Janus Henderson InvestorsreportedNew York
Viking Global InvestorsreportedStamford
Funding
SEC filings, press & company announcements$65M disclosed across 1 round · 2026
- $65MSeries CJun 2026 · 2 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Fierce Biotech Fundraising Tracker '26: InduPro assembles $77M; Vaderis nets $152M series Bfiercebiotech.com · Aug 2026Frequently asked questions
- What does Triveni do?
- Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases. The biotech company focuses on targeting the underlying biology of disease to change the standard of care for patients.
- Who are Triveni's investors?
- Triveni's investors include Atlas Venture, Borealis Ventures, Borealis Ventures, Magnetic Ventures, OrbiMed, Ascenta Capital, Fidelity Investments, Invus and 2 more.
- How much funding has Triveni raised?
- Triveni has disclosed $65M raised across 1 round.